| SHORT COMMUNICATION
|Year : 2020 | Volume
| Issue : 1 | Page : 44-48
Fasting insulin levels correlate with the frequency of hypoglycemic events in people with type 2 diabetes on treatment with sulfonylureas: A pilot study
Konstantinos Kolokas1, Theocharis Koufakis2, Iakovos Avramidis3, Spyridon Gerou4, Maria Chatzidimitriou5, Kyriakos Kazakos6, Kalliopi Kotsa1
1 3rd Local Primary Care Unit (TOMY), Division of Endocrinology and Metabolism and Diabetes Center, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece
2 First Department of Internal Medicine, Division of Endocrinology and Metabolism and Diabetes Center, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece
3 Department of Internal Medicine, Diabetes Center, G. Papanikolaou General Hospital, Thessaloniki, Greece
4 Medical Laboratories Analysis Iatriki S.A., Thessaloniki, Greece
5 Department of Medical Laboratories, Alexander Technological Educational Institute, Thessaloniki, Greece
6 Department of Nursing, Alexander Technological Educational Institute, Thessaloniki, Greece
AIMS AND OBJECTIVES: We aimed to explore whether fasting insulin levels correlate with the risk of hypoglycemia in people with Type 2 diabetes (T2D) receiving sulfonylureas (SUs).
MATERIALS AND METHODS: Our study included 58 individuals with T2D who had been on treatment with SUs, but not insulin, for more than 2 years. Confirmed hypoglycemic episodes during the past year were self-reported by the patients, and a potential relationship of hypoglycemic event frequency with fasting insulin levels was investigated.
RESULTS: Fasting insulin concentrations were found to have a low positive and statistically significant correlation with the number of cases of mild hypoglycemia per year (ρ = 0.279/P = 0.034) and a moderately positive and statistically significant correlation with the number of severe hypoglycemic events per month (ρ = 0.349/P = 0.007) and per year (ρ = 0.39/P = 0.002).
CONCLUSION: Our results suggest that fasting insulin levels might be a predictor of the risk of hypoglycemia in people with T2D on treatment with SUs.
Prof. Kalliopi Kotsa
1St. Kiriakidi Street, 54636 Thessaloniki
Source of Support: None, Conflict of Interest: None
[FULL TEXT] [PDF]*